Loading…
NanoViricides, Inc. is projected to rise to $2.10 by 2027, a +20% move from its current price of $1.75. NNVC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.64 | $1.75 | $1.86 | -0.09% |
| May 30 | $1.60 | $1.75 | $1.91 | -0.18% |
| May 31 | $1.57 | $1.75 | $1.94 | -0.27% |
| Jun 1 | $1.54 | $1.74 | $1.97 | -0.37% |
| Jun 2 | $1.52 | $1.74 | $2.00 | -0.46% |
| Jun 3 | $1.49 | $1.74 | $2.03 | -0.55% |
| Jun 4 | $1.48 | $1.74 | $2.05 | -0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.48 | $1.74 | $2.05 | -0.64% |
| Week 2 | $1.37 | $1.73 | $2.18 | -1.28% |
| Week 3 | $1.29 | $1.72 | $2.28 | -1.91% |
| Week 4 | $1.23 | $1.71 | $2.37 | -2.54% |
| Week 5 | $1.17 | $1.69 | $2.45 | -3.16% |
| Week 6 | $1.13 | $1.68 | $2.52 | -3.78% |
| Week 7 | $1.08 | $1.67 | $2.58 | -4.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NanoViricides, Inc. is a clinical-stage nano-biopharmaceutical company focused on discovering, developing, and commercializing drugs to combat viral infections. Its portfolio centers on NV-387 for RSV and influenza, with completed phase 1a/1b human trials evaluating safety and tolerability.
NV-387 is also an active ingredient in COVID formulations such as NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, which are in phase 1a/1b trials to enable body-weight-based dose titration for pediatric treatments.
The company also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized, including an injectable solution delivered as a lung fog via nebulizer devices. In addition, NanoViricides develops NV-HHV-1, a skin cream for Shingles, with an oral NV-HHV-1 drug for HSV-1 cold sores and HSV-2 genital ulcers, and other drug candidates in the HIVCide program, along with Nanoviricide platform technology to treat various viruses. NanoViricides, Inc.
was incorporated in 2005 and is headquartered in Shelton, Connecticut.
NanoViricides, Inc. (NNVC) is categorized in Healthcare and is currently priced at $1.64. It holds a market rank of 4719 and a market cap of $37.36M.
The price outlook reflects a mixed near-term and stronger longer-term potential. The forecast shows a neutral stance in 2026, with a path toward bullish momentum in subsequent years. The 2026 avg price is $1.64, rising to a 2030 avg of $2.59 and a 2050 avg of $21.34, with a 2050 max of $49.08.
These figures are estimates and not guarantees, but they illustrate potential upside over the multi-year horizon.
A major floor 51.4% below — a decisive break under it would weaken the trend.
The nearest floor, 33.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 22.5% above — clearing it would confirm fresh momentum.
Key NNVC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NNVC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.61 | Buy | $1.63 | Buy |
| MA 10 | $1.61 | Buy | $1.59 | Buy |
| MA 20 | $1.51 | Buy | $1.51 | Buy |
| MA 50 | $1.26 | Buy | $1.34 | Buy |
| MA 100 | $1.16 | Buy | $1.27 | Buy |
| MA 200 | $1.29 | Buy | $1.28 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.69 | Neutral |
| Stoch RSI (14) | 45.11 | Neutral |
| CCI (20) | 149.37 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 12.90 | Buy |
| Bollinger %B (20,2) | 0.92 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.25 | Buy |
| Awesome (5,34) | 0.23 | Buy |
| Ultimate (7,14,28) | 66.31 | Neutral |
| Momentum (10) | 0.25 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 1.62 | Buy |
| ADX (14) | 22.89 | Buy |
| ATR (14) | 0.09 | Info |
The 30-day technical picture shows bullish sentiment, with RSI14 at 60. The stock trades around the 50-day and 200-day moving averages, with the SMA50 at $1.24 and the SMA200 at $1.29.
The near-term trading range spans $1.14 to $2.36, with a current support level at $1.04 and a resistance at $1.74. Annualized volatility is 100%, underscoring substantial price swings on a yearly basis.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.85 | $1.75 | $2.70 | 0% | Neutral | |
| $1.51 | $2.10 | $3.16 | +20% | Bullish | |
| $1.48 | $2.19 | $3.50 | +25% | Bullish | |
| $1.44 | $2.23 | $3.74 | +28% | Bullish | |
| $1.90 | $3.09 | $5.38 | +76% | Bullish | |
| $2.59 | $4.40 | $7.94 | +151% | Bullish | |
| $2.79 | $4.94 | $9.18 | +182% | Bullish | |
| $2.95 | $5.44 | $10.39 | +211% | Bullish | |
| $2.71 | $5.20 | $10.17 | +197% | Bullish | |
| $2.76 | $5.51 | $11.03 | +215% | Bullish | |
| $3.98 | $8.85 | $19.46 | +406% | Bullish | |
| $12.81 | $28.46 | $65.47 | +15.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.85 | $1.75 | $2.08 | +0.00% |
| June 2026 | $1.42 | $1.70 | $2.11 | -2.88% |
| July 2026 | $1.32 | $1.61 | $2.05 | -5.30% |
| August 2026 | $1.36 | $1.68 | $2.18 | +4.35% |
| September 2026 | $1.41 | $1.76 | $2.32 | +4.63% |
| October 2026 | $1.37 | $1.73 | $2.31 | -1.66% |
| November 2026 | $1.40 | $1.79 | $2.42 | +3.41% |
| December 2026 | $1.53 | $1.97 | $2.70 | +10.24% |
Click any year to see its month-by-month NNVC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NanoViricides, Inc.'s 2026 outlook centres on $1.75, within a $0.85 to $2.70 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NNVC could reach as high as $3.16, with a base case around $2.10 and support toward $1.51 — roughly +20% from $1.75. Buyers look set to stay in control over this stretch.
Expect NNVC to range from $1.48 to $3.50 through 2028. The $2.19 average target implies a +25% move from current prices. That is up +4% on the projected 2027 average. Momentum favours further upside here.
The NNVC price prediction for 2029 points to an average of $2.23 (low $1.44, high $3.74) — a potential gain of +28% on today's $1.75. Buyers look set to stay in control over this stretch.
In 2030, NNVC is projected to trade between $1.90 and $5.38, averaging $3.09 — a potential gain of +76% from today's $1.75. That is up +38% on the projected 2029 average. Momentum favours further upside here.
NanoViricides, Inc.'s 2031 outlook centres on $4.40, within a $2.59 to $7.94 range. That is up +43% on the projected 2030 average. That marks a +151% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, NNVC could reach as high as $9.18, with a base case around $4.94 and support toward $2.79 — roughly +182% from $1.75. Momentum favours further upside here.
Expect NNVC to range from $2.95 to $10.39 through 2033. The $5.44 average target implies a +211% move from current prices. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The NNVC price prediction for 2034 points to an average of $5.20 (low $2.71, high $10.17) — a potential gain of +197% on today's $1.75. Momentum favours further upside here.
In 2035, NNVC is projected to trade between $2.76 and $11.03, averaging $5.51 — a potential gain of +215% from today's $1.75. That is up +6% on the projected 2034 average. Buyers look set to stay in control over this stretch.
NanoViricides, Inc.'s 2040 outlook centres on $8.85, within a $3.98 to $19.46 range. That is up +61% on the projected 2035 average. That marks a +406% change versus current levels. Momentum favours further upside here.
By 2050, NNVC could reach as high as $65.47, with a base case around $28.46 and support toward $12.81 — roughly +15.3x from $1.75. Buyers look set to stay in control over this stretch.
Investing $1,000 in NNVC today (≈ 571.428571 NNVC) could be worth
$16,264.7
+$15,264.7 (+1526%) by 2050 · US Dollar
Based on the average projected NNVC price of $28.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NNVCwould be worth at today's price.
$1,000 invested in NNVC on May 27, 2025 (≈ 584.795309 NNVC) would be worth
$1,023.39
+$23.39 (+2.3%) today · 1.02× · US Dollar
Based on a NNVC entry price of $1.71 vs. today's $1.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.62 | $1,080.25 | +8.0% |
| 1 month ago | $1.25 | $1,400 | +40.0% |
| 3 months ago | $1 | $1,750 | +75.0% |
| 6 months ago | $1.22 | $1,434.43 | +43.4% |
| 1 year ago | $1.71 | $1,023.39 | +2.3% |
| All time (5.0y) ago | $3.65 | $479.45 | -52.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NNVC forecast.
Our base-case forecast reaches $3.50 around 2031.
Implied market cap at $3.50: $79.73M
The multi-year forecast envisions expanding upside with a generally bullish stance in the longer horizon. For 2026 the avg price is $1.64 with a neutral sentiment and a min of $0.85 and a max of $2.54. By 2027 the avg rises to $1.90 with a max of $2.86 and a ROI of 15.7, maintaining a neutral stance.
In 2028 the avg is $1.98 (max $3.17) with a ROI of 20.7 and a bullish sentiment, followed by 2029 with an avg of $2.00 (max $3.35) and a ROI of 21.7.
The forecast shows further upside in 2030 (avg $2.59, min $1.59, max $4.52; ROI 57.9; bullish), then stronger gains in 2031 (avg $3.69, max $6.66; ROI 124.9) and 2032 (avg $4.13, max $7.67; ROI 151.6), continuing through 2033 (avg $4.46, max $8.53; ROI 172.1) and 2034 (avg $4.33, max $8.48; ROI 164).
The uptrend persists into 2035 (avg $4.47, max $8.96; ROI 172.8). In the 2040 horizon, the avg climbs to $6.99 (max $15.39; ROI 326.5). By 2050, the avg is $21.34 with a max of $49.08 and ROI of 1201.1, supported by a bullish sentiment.
These are estimates, not guarantees, and reflect potential upside across a long investment horizon with inherent uncertainty.
Tap a question to reveal the answer.
2030 min $1.59, avg $2.59, max $4.52; ROI 57.9; sentiment BULLISH.
The forecast shows 2040 max $15.39 and 2050 max $49.08, with 2050 average $21.34; indicating potential above $10 in the longer run.
The 2026 forecast is NEUTRAL, 2027 NEUTRAL, and the outlook becomes BULLISH from 2028 onward through 2050.
Current price is $1.64 and market cap is $37.36M.
RSI14 is 60, sentiment BULLISH, SMA50 is $1.24, SMA200 is $1.29. The 30-day range is $1.14-$2.36 with support at $1.04 and resistance at $1.74; annualized volatility is 100%.
NanoViricides, Inc. Community Discussion
0Share your NanoViricides, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.